Healthcare - Biotechnology - NASDAQ - US
$ 24.41
-2.05 %
$ 1.19 B
Market Cap
-13.05
P/E
BALANCE SHEET
272 M
ASSETS
26 M
LIABILITIES
246 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Enliven Therapeutics, Inc.
| Current Assets | 266 M |
| Cash & Short-Term Investments | 253 M |
| Receivables | 0 |
| Other Current Assets | 13 M |
| Non-Current Assets | 5.72 M |
| Long-Term Investments | 0 |
| PP&E | 1.06 M |
| Other Non-Current Assets | 4.65 M |
| Current Liabilities | 25.9 M |
| Accounts Payable | 532 K |
| Short-Term Debt | 335 K |
| Other Current Liabilities | 25 M |
| Non-Current Liabilities | 67 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 67 K |
Balance Sheet
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Cash & Cash Equivalents | 100.1 | 75.5 | 110.0 | 130.4 | 4.9 | 7.4 | 9.7 |
| Short Term Investments | 153.0 | 0 | 42.0 | 40.5 | 24.0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 13.0 | 2.2 | 0.6 | 0.2 | 1.7 | 0.3 | 0.6 |
| Total Current Assets | 266.2 | 77.8 | 110.7 | 130.6 | 30.6 | 7.7 | 10.2 |
| PP&E | 1.1 | 1.5 | 1.0 | 0.4 | 0.4 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 0 | 54 K | 0.2 | 88 K | 88 K | 0 | 0 |
| Other Long Term Assets | 4.7 | 4.0 | 1.5 | 88 K | 2.1 | 0 | 0 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 271.9 | 83.3 | 113.3 | 131.0 | 33.3 | 7.7 | 10.2 |
| LIABILITIES | |||||||
| Accounts Payable | 0.5 | 3.4 | 2.5 | 0.8 | 1.7 | 0.9 | 0.4 |
| Short Term Debt | 0.3 | 0.3 | 0.2 | 0.1 | 0 | 0 | 0 |
| Other Current Liabilities | 25.0 | 6.0 | 3.1 | 0.6 | 2.5 | 0.9 | 0.4 |
| Total Current Liabilities | 25.9 | 9.7 | 5.8 | 1.5 | 4.2 | 1.8 | 0.8 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0.7 |
| Deferred Tax Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 67 K | 150.4 | 150.5 | 149.8 | 0.2 | 32.2 | 0 |
| Total Liabilities | 26.0 | 160.1 | 156.2 | 151.3 | 4.4 | 1.8 | 1.5 |
| EQUITY | |||||||
| Common Stock | 41 K | 1 K | 1 K | 1 K | 4 K | 4 K | 4 K |
| Retained Earnings | (154.4) | (82.9) | (45.2) | (20.5) | (54.8) | (31.3) | (20.0) |
| Other Accumulative Comprehensive Income/Loss | 0.1 | (0.1) | 16 K | 4 K | 32 K | 0 | 0 |
| Total Equity | 245.9 | (76.8) | (42.9) | (20.3) | (48.8) | (26.3) | (15.5) |
| Total Liabilities and Equity | 271.9 | 83.3 | 113.3 | 131.0 | 33.3 | 7.7 | 10.2 |
| SHARES OUTSTANDING | |||||||
| Common Shares Outstanding | 35.5 | 3.1 | 2.3 | 3.5 | 4.3 | 4.3 | 4.3 |